ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Anixa Biosciences Inc
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026
$2.61−0.06 (-2.25%)
Close on Oct 19, 2026
- Market cap
- $89.22M
- P/E (TTM)
- –
- Dividend yield
- –
Anixa Biosciences Inc revenue by segment
By business segment
| Operating income | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other [Member] | -$13.00K | -$11.00K | -$3.00K | -$14.00K | -$10.00K | -$10.00K | -$19.00K | – | – | – | – | – | +30.0% |
| CAR-T Therapeutics [Member] | -$843.00K | -$926.00K | -$1.05M | -$1.19M | -$1.04M | -$986.00K | -$1.24M | – | – | – | – | – | -19.0% |
| Cancer Vaccines [Member] | -$1.88M | -$1.71M | -$1.66M | -$1.87M | -$1.39M | -$2.01M | -$2.13M | – | – | – | – | – | +35.8% |
By product or service
By region
From the segment and revenue-disaggregation notes of Anixa Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.